Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock
February 27, 2019 20:07 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
February 26, 2019 16:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
February 25, 2019 16:05 ET
|
Alder BioPharmaceuticals, Inc.
- Completes eptinezumab’s Biologics License Application (BLA) submission - - Remains on track for eptinezumab’s commercial launch in Q1-2020 - - Strengthens leadership team with the...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 22, 2019 16:16 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Submits Biologics License Application to the U.S. Food and Drug Administration for Eptinezumab
February 22, 2019 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 21, 2019 17:17 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial and Operating Results
February 19, 2019 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2019 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 25, 2019 16:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Appoints Paul Streck, M.D. Chief Medical Officer
January 17, 2019 16:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...